Literature DB >> 6951071

5-Fluorouracil, 1,3-bis(2-chloroethyl)-1-nitrosourea, and 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea: effect on the human granulopoietic system.

H P Lohrmann, K A Lepp, W Schreml.   

Abstract

The reaction pattern of the normal (nonleukemic) human granulopoietic system to single-agent treatment with 5-fluorouracil (FUra) and to a combination of FUra with two nitrosoureas, 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea (MeCCNU), was studied serially by morphologic and in vitro culture methods. The granulopoietic toxicity of FUra was acute and rapidly (by day 21) reversible. In contrast, the toxicity of the combination regimens was long lasting. Evidence exists that an early toxicity (that of FUra) and a delayed toxicity (that of the nitrosourea) were overlapping. Toxicity of BCNU and MeCCNU was most pronounced at the level of in vitro colony-forming units of the granulopoietic system (G-CFUc). G-CFUc compartments of bone marrow and peripheral blood continued to be reduced in size at the time of recovery of the peripheral blood granulocyte count from nitrosourea-induced toxicity. This finding may be responsible for the cumulative toxicity to the human hematopoietic system that frequently has been observed after repeated administration of nitrosourea compounds.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6951071

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  7 in total

1.  Medroxyprogesterone acetate does not protect human bone marrow progenitor cells exposed to adriamycin in vitro.

Authors:  G E Umbach; G Spitzer; B Drewinko; G Gercovich; G Hortobagyi
Journal:  Breast Cancer Res Treat       Date:  1985       Impact factor: 4.872

2.  Adjuvant chemotherapy in gastric cancer.

Authors:  P Schlag
Journal:  World J Surg       Date:  1987-08       Impact factor: 3.352

3.  Role of culture conditions and exposure duration in determining sensitivity of human bone marrow progenitor cells to methotrexate.

Authors:  G E Umbach; G Spitzer; J A Ajani; V Hug; H Thames; F B Rudolph; B Drewinko
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

4.  Survival of human bone marrow cells after in vitro treatment with 12 anticancer drugs and implications for tumor drug sensitivity assays.

Authors:  G E Umbach; V Hug; G Spitzer; B Tomasovic; H Thames; J A Ajani; B Drewinko
Journal:  J Cancer Res Clin Oncol       Date:  1985       Impact factor: 4.553

5.  Interstitial chemotherapy with biodegradable BCNU (Gliadel) wafers in the treatment of malignant gliomas.

Authors:  Daniela A Bota; Annick Desjardins; Jennifer A Quinn; Mary L Affronti; Henry S Friedman
Journal:  Ther Clin Risk Manag       Date:  2007-10       Impact factor: 2.423

6.  Interstitial chemotherapy for malignant glioma: Future prospects in the era of multimodal therapy.

Authors:  Antonella Mangraviti; Betty Tyler; Henry Brem
Journal:  Surg Neurol Int       Date:  2015-02-13

Review 7.  Genetic Strategies for HIV Treatment and Prevention.

Authors:  Alexander Falkenhagen; Sadhna Joshi
Journal:  Mol Ther Nucleic Acids       Date:  2018-09-29       Impact factor: 8.886

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.